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Abstract
Community-acquired pneumonia is a common disease which yearly affects 1 of 100 persons and it 
is the most common infection diagnosis in all in-patient hospital care. The swedish society of 
infectious diseases has set up a number of targets regarding the quality of pneumonia care in 
departments of infectious diseases. The targets means that CRB65-score (=a prognostic tool that 
takes into account the presence of confusion, the respiratory rate, blood pressure and age) should be 
calculated and noted for at least 50 % of patiens with suspected pneumonia,  blood cultures and 
airway cultures should be taken from all these patients and at least 75 % of the patients should have 
PcV or PcG as initial treatment. The result of target accomplishment is documented in a national 
quality register (NQPR).
The majority of patients who is treated for community-acquired pneumonia in inpatient hospital 
care is however treated in departments of internal medicine. Therefore, it is interesting to 
investigate the target accomplishment in these departments and compare the results with the results 
from departments of infectious diseases. 
The aim with this master thesis in medicine is to compare patients who have been treated for 
community-acquired pneumonia in departments of internal medicine with patientes who have been 
treated in departments of infectious diseases, with respect to antibiotic treatment, the use of CRB65-
score for therapy choise and the use of cultures. 
100 medical records from patients treated for community-acquired pneumonia in departments of 
internal medicine in NU-sjukvården during 2012 were examined and the results were compared 
with data from the national pneumonia register.
The result shows that CRB65-score was not mentioned in any enrollment record, and enough 
information to calculate the CRB65-score was missing in 51 % of the records. Blood cultures were 
taken in 83 % (91.3 % in the NQPR) and airway cultures were taken in 21 % of the patients (76.3 % 
in the NQPR). 74 % received PcV or PcG as initial antibiotic, which is a higher number than in the 
NQPR. 
Conclusion: The target to treat at least 75 % with PcV or PcG was almost achieved in the 
departments of internal medicine, as 74 % got these antibiotics. The other targets were not achieved 
neither in departments of internal medicine, nor in departments of infectious diseases.
1. Introduction
1.1 Background
Community-acquired pneumonia is a common disease that is potentially life-threatening. [1]. The 
annual incidence is 1 of 100, and pneumonia primarily affects elderly. [2].
The swedish society of infectious diseases has set up a number of targets regarding the quality of 
pneumonia care for patientes treated in departments of infectious diseases. These targets means that 
blood culture and some kind of airway culture must be taken from all patients with suspected 
pneumonia. Further, the CRB-65-score (=a prognostic tool that takes into account the presence of 
confusion, the respiratory rate, blood pressure and age), should be documented for at least 50 % of 
the patients at time for enrollment and for the patients with CRB-65-score 0-2 at least 75 % should 
be given PcV (fenoximethyl penicillin) or PcG (benzyl penicillin) as initial treatment.  The reason 
for this is to counteract too much use of broad-spectrum antibiotics, as this contributes to the 
development of resistant bacterias. The result of target accomplishment is documented in a national 
pneumonia register.
The majority of patients who is treated for community-acquired pneumonia in inpatient hospital 
care is however treated in departments of internal medicine. Therefore, it is interesting to 
investigate the target accomplishment in these departments and compare the results with the results 
from departments of infectious diseases. 
1.2 Concepts and abbreviations
Pneumonia: the definition of pneumonia is symptoms of lower respiratory tract infection, such as 
fever, cough, dyspnoea, sudden fatigue, respiratory correlated chest pain and/or abnormal breath 
sounds combined with typical radiological findings.[2]
Community-acquired pneumonia (CAP): hereby means pneumonia acquired outside hospital or 
long-time nursing home. Pneumonia is not considered as community-acquired if the patient has 
been treated in inpatient hospital care or long-time nursing home for the last month. 
The national pneumonia register (NQPR): an annual report that contains data from patients 
treated in all departments of infectious diseases in Sweden. Patients treated in departments of 
internal medicine are thus not included.
CRB-65-score: a prognostic score which is used when making decisions about the care of patients 
with suspected pneumonia, for example which level of in-hospital care (intensive care unit or 
common ward) the patient needs, and which antibiotic treatment to use initially. Parameters that are 
investigated are confusion, respiratory rate, blood pressure and age. Presence of confusion, 
respiratory rate > 30, systolic blood pressure < 90 or diastolic blood pressure < 60, and age > 65 
years gives one point each. Thus we get a total CRB-65 result between 0 and 4.[3]
However, CRB-65-score has some weaknesses. It is best used for predicting the mortality rate on 
population level, and it is not enough in the management of patients with suspected pneumonia. For 
example, information about oxygen saturation is not taken into a account. A recent spanish study 
proposes a modification called CORB-75, where CRB-65 is completed with measurement of 
oxygen saturation, and the age criteria is changed to 75 years. [4]
PcV and PcG: with PcV means fenoximethyl penicillin and with PcG means benzyl penicillin.
COPD: hereby means chronic obstructive pulmonary disease.
MS: hereby means multiple sclerosis.
ICU: hereby means intensive care unit.
1.3 Etiology
S. pneumoniae (pneumococci) is the most common pathogen that causes pneumonia among patients
who requires in-hospital care. The next most common pathogen in this patient group is H. 
Influenzae, followed by M. Pneumoniae (mycoplasma). It is noteworthy that H. Influenzae is a 
more common pathogen among patients with CRB-65 2-4, while mycoplasma is more common 
among patients with CRB-65 0-1.There is also an age difference as mycoplasma mainly affects 
younger persons under 50 years, while pneumococci and H. Influenzae affects all age groups.
Outside of the bacterial pathogens above, viruses are also a common cause of community-acquired 
pneumonia, primarily influenza viruses during the influenza season, but also respiratory syncytial 
virus (RSV) and adenoviruses. More uncommon pathogens are Legionella, S. Aureus, 
Clamydophila psittaci, Clamydophila pneumoniae (TWAR), M. catarrhalis and gram-negative 
enteric bacterias such as E. Coli. [5] 
1.4 Diagnostics
There is not one single test that alone can tell if the patient has pneumonia. Several different tests 
and investigations are necessary. Clinical examination should include heart and lung auscultation, 
lung percussion, calculate respiratory rate, measuring pulse, blood pressure, temperature and 
oxygen saturation [3].
Blood sample should be taken for chemical analysis. Hb, leukocytes trombocytes, CRP, creatinine, 
albumin, sodium, potassium and ALAT should be analysed for all patients with suspected 
pneumonia. In some cases an arterial blood gas analysis should be done: patients with CRB-65 2-4, 
impaired conciousness, smokers, COPD-patients and if the oxygen saturation is under 92% .[2]
Legionella and pneumococci antigens can be detected in a urine sample. 
Radiological methods that can be used are plain X-ray and CT scan. Plain X-ray gives in most cases 
enough information to establish the diagnosis, and differential diagnoses such as pneumothorax, 
pleural fluid and tuberculosis can be seen with this method. Lung embolism is another important 
differential diagnosis, this is however more difficult to detect with a plain X-ray and typically 
requires a CT scan. 
Cultures and PCR are very important in the management of patients with suspected pneumonia. It is 
the only way to verify which pathogen has caused the disease, and thus choose the right therapy. By 
choosing a targeted antibiotic treatment we decrease the risk of resistance development. Since there 
is a high incidence of bacteremia among these patientes, blood cultures should be taken before 
antibiotic treatment starts. 
Airway cultures should also be taken. There are different types of airway cultures. Nasopharyngeal 
culture and sputum culture are the most common. Nasopharyngeal culture is quick and easy to take, 
but it is important to take into account that it shows which bacterias that are found in the pharynx, 
and not in the lower airways. Sputum culture indicates which bacterias that are in the lower airways, 
but it always becomes contaminated with pharynx- and mouth flora. It can be difficult for the 
patient to produce a sputum culture, especially for seriously ill patients [3].
Other ways to get an airway culture is through bronchoscopy with a protected brush or by broncho-
alveolar lavage. These are more invasive methods that requires special personnel, takes longer time 
and causes more discomfort for the patient than the methods mentioned above. The advantage is 
that we get a culture from the right location, free from pharynx- and mouth flora.
There are also typical clinical findings that can give us an indication about the ethiology. A sudden 
onset and affected general condition is typical för pneumococci. Other findings that are typical for 
pneumococci are yellow-green expectoration, high leukocytes (> 15) and high CRP. A COPD-
patient (a patient with chronic obstructive pulmonary disease) with gradually increased cough and 
reduced oxygen saturation should make us think abut H. influenzae as a possible cause. A young, 
relatively unaffected patient with coughing attacks and normal breath sounds may be caused by 
mycoplasma, especially if there is an ongoing mycoplasma epidemic. [6]. After all, the only way to 
be sure about the ethiology is through the use of cultures or PCR (poly chain reaction).
Viruses as a cause to pneumonia is also important to keep in mind, especially during influenza 
season. Common airway viruses like influenza viruses A and B, adenoviruses, rhinoviruses, 
parainfluenza viruses and corona viruses can cause pneumonia.  A patient with viral pneumonia 
often have cough, myalgia and headache, whereas pleuritic pain is less common than in patients 
with pneumococcal pneumonia. The CRB-65-score is usually lower than with bacterial ethiology. 
The ethiology can also be mixed, with both viruses and bacterias. Mixed ethiology is often a cause 
to more severe illness. Since viruses are not detected in cultures, PCR test is necessary to establish a 
viral ethiology. [7]
Older patients (> 65 years) may present with atypical symptoms. Cough, fever, expectoration and 
dyspnoea may be missing, and the patient may instead be confused or show a high respiration rate 
[8].
1.5 Treatment
Pneumonia is one of the airway infections that normally shall be treated with antibiotics. This is 
because pneumonia is a serious disease which is potentially fatal, and bacterias is the most common 
cause of the disease [9].  Since pneumococci is the most common pathogen, and also the most 
dangerous, it must be covered by the empirical treatment. 
A betalactam antibiotic like phenoxymethyl penicillin (PcV) for oral administration or benzyl 
penicillin (PcG) for parenteral administration covers pneumococci. This should be the first choiche, 
as most pneumococci are sensitive for these antibiotics. Another advantage is that the side effects 
are mild, and mainly consists of nausea, diarrhea and skin eruptions. Cephalosporins are other kinds 
of beta-laktam antibiotics, which are effective against pneumococci. These are however more likely 
to cause evolution of resistant bacterias. [10] 
A lot of research have been done regarding the antibiotic treatment of community-acquired 
pneumonia, as if atypical pathogens should be covered routinely. A swedish multi-center study in 
2002 showed that the narrow treatment with penicillin as monotherapy did not lead to increased 
mortality or increased lenght of hospital stay. [11]
A multinational meta-analysis consisting of 18 research studies with totally 6749 patients compared 
the usage of betalactam antibiotics with treatment effective against atypical pathogens among 
patients with non-severe pneumonia in primary care and out-patient hospital clinics. The research 
question was if the coverage of atypical pathogens led to decrease in therapy failure compared with 
betalactam antibiotics. The result showed no difference in therapy failure depending on which 
treatment was given. When the material was divided into subgroups according to ethiology, there 
were a statistically significant increase in therapy failure among the patients who had pneumonia 
caused by legionella when they were treated with only betalactam antibiotics. [12]
Another multinational meta-analysis consisting of 24 research studies analyzed in total 5015 
patients who were hospitalized because of community-acquired pneumonia. It compared treatment 
with atypical coverage with treatment without atypical coverage (mainly beta-actam antibiotics) 
with respect to mortality, clinical improvement, bacterial eradication and side effects. The result 
showed no difference in mortality. The clinical improvement was higher when treatment with 
atypical coverage was given. There was no difference in bacterial eradication. Side effects (mainly 
abdominal pain and diarrhea) were more common among patients who received treatment without 
atypical coverage. [13]
The swedish guidelines for pneumonia treatment recommend PcV or PcG as first choice for normal 
patients when CRB-65-score is 0-1. With normal patient means a immunocompetent patient with no 
severe underlying lung disease and no allergy to penicillin. When CRB-65-score is 2, PcV or PcG is 
also the first choice, if nothing inspires suspicion about atypical pathogenesis. Factors that shuold 
make us suspect atypical pathogenesis are for example if the patient has recently been abroad 
(increased risk for legionella) or if there is an ongoing mycoplasma epidemic. If we suspect an 
atypical ethiology, normal patients should have erytromycin or doxycyklin [6]. 
When CRB-65-score is 3-4, it is according to the guidelines, necessary to choose a therpy with 
broader spectrum. For normal patients this means a third-generation cephalosporin like cefotaxim, 
combined with erytromycin. An alternative is high-dose PcG combined with a quinolone. [6]
During influenza season it is recommended to take PCR test for influenza viruses if the anamnesis 
and clinical examination raise a suspicion about viral pathogenesis. If influenza viruses are 
detected, treatment with oseltamivir is recommended for patients belonging to a risk group or if the 
disease is severe. Risk groups are patients older than 65 years, pregnant women in the second or 
third trimester, immunosuppressed patients, obese patients with a body mass index (BMI) > 40 and 
patients with any of the following chronic diseases: heart- or lung disease, unstable diabetes, athma, 
liver- or renal failure or a neurological disease that affects breathing [14]. Oseltamivir treatment 
decreases risk for death and reduce the need for unnecessary antibiotic treatment if the ethiology 
has been proven to be influenza viruses A or B. [15]
The recommended treatment time is 7 days for both mild and severe pneumonia. Exception is if the 
cause is legionella, then 10 days treatment is recommended [1].
1.6 Antibiotic resistance
Since the etiology is most often unknown when the treatment starts, it is necessary to choose 
antibiotics empirically. Then it might be tempting to choose an unnecessarily broad antibiotic just to 
be sure not to miss any pathogen. This is however not a sustainable strategy, since the use of broad-
spectrum antibiotics is driving the development of resistant bacterias. 
Compared with other European countries, Sweden has less problems with resistant bacterias[16]. 
However, it is an increasing problem, especially in hospital environment. Between 1995 and 2004, 
pneumococci with decreased sensitivity to penicillin increased from 4 % to 6 % in nasopharyngeal 
cultures, and there were also an increase in resistance to erytromycin, tetracyklin and trimetoprim-
sulfa among pneumococci. This development took place despite a general decrease in antibiotic 
prescription during this time. [17]
Antibiotic resistance can occur through four different mechanisms; reduced penetration of the 
antibiotic through the bacteria cell wall, decreased binding, bacterial enzymes that break down 
antibiotics, and finally through increased outflow of antibiotic from the bacteria. The bacteria can 
exhibit one or more of these mechanisms. [10]
The two most important mechanisms for betalactam antibiotic resistance are either when the 
bacterias produce beta lactamase, or by change of the penicillin-binding proteins (PBP) on the 
bacteria surface. Increased efflux or reduced permeability are also occuring mechanisms, but these 
are less common.
Beta lactamase is an enzyme that hydrolyzes, and thereby destroys, the betalactam ring in the 
antibiotic. Thus, the bacterias become resistant to penicillin, and even against some cephalosporins. 
There are several kinds of beta lactamases, which explains why the resistance pattern may look 
different among different bacterias. Beta lactamases can be either cromosomal or plasmid-borne. 
The plasmid-borne beta lactamases have an extended spectrum and the bacterias become resistant to 
more kinds of cephalosporins and also carbapenems. These beta lactamases are called ESBL 
(=extended spectrum beta lactamase), and are typically found in E.coli and Klebsiella species [18]. 
ESBL producing bacterias are the type of resistant bacterias that are increasing most in Sweden. 
Between 2007 and 2012, ESBL producing bacterias increased from about 2000 cases to over 7000 
cases. [19]
There are however ways to counter the beta lactamase. Clavulanic acid and tazobactam inhibits beta 
lactamase and are therefor used as a supplement to betalactam antibiotics when treating bacterias 
that produce beta lactamase. Clavulanic acid is often used together with amoxicillin for oral 
distribution, and tazobactam is often used together with piperacillin for parenteral distribution [20].
Change of the penicillin-binding proteins decreases the affinity for, and thereby causes resistance to, 
penicillin and cephalosporins among pneumococci, H. Influenzae and S. Aureus. There are several 
kinds of changes in the PBP, and that is why bacterias can be resistant to some antibiotics but not to 
others. Some S. aureus have a PBP-change that makes them resistant to all kinds of betalactam 
antibiotics. These are called MRSA (meticillin resistant S. Aureus) [18].
SwedRes is an annual report on antibiotic prescribing and resistance in Sweden. According to this 
report, pneumoococci with decreased sensibility for penicillin were found in 5 % of blood cultures 
and 6.6 % of airway cultures 2012. The presence of these bacteria have not increased during the 
recent years. On the contrary, it can be seen a small reduction between 2007 and 2012. [19]
H.influenzae has especially developed resistance against betalactam antibiotic and trimetoprim-
sulfa. In 2011, 18 % of H.influenzae found in airway cultures were producing beta lactamase. [21] 
2. Aim and research questions
2.1 Aim
The aim is to compare patients who have been treated for community-acquired pneumonia in 
departments of internal medicine with patientes who have been treated in departments of infectious 
diseases, with respect to antibiotic treatment, the use of CRB-65-score for choise of treatment and 
the use of cultures. 
2.2 Research questions
Which was the median age of the patients treated in departments of internal medicine?
How many were men and how many were women?
Was any airway culture taken, and if so, which kind of airway culture?
Were blood cultures taken?
Were there enough information to caculate the CRB-65-score at the time for enrollment?
Was the CRB-65-score documented in the enrollment record?
Which infection parameters were investigated at enrollment?
Was urine sample for pneumococcal antigen and legionella antigen taken?
Was PCR test for mycoplasma and viruses taken?
Was any radiological method used for diagnostics?
What antibiotics were used initially?
What antibiotics were used after 72 hours?
What antibiotics were used as follow-up treatment?
How many days lasted the antibiotic treatment (iv and total)?
For how long did the patients stay in hospital?
Were patients treated in ICU, with respirator or CPAP/BiPAP?
What was the mortality rate during hospital stay and within 30 days?
Was any palliative descision taken, such as restrict or end treatment?
Was a descision about no CPR taken?
Were there any differences with respect to the parameters above compared with patients treated in 
departments of infectious diseases?
3. Material and methods
The thesis is based on examination of 100 medical records regarding patients who were treated for 
community-acquired pneumonia in departments of internal medicine in NU-sjukvården (NÄL and 
Uddevalla hospital) during 2012, and comparison with data from the national pneumonia register 
(NQPR). The patients were selected by requesting a list of all patients who were discharged from 
departments of internal medicine during 2012 with any of the following ICD diagnoses:
J13 – J18 as main diagnosis, or  as secondary diagnosis to bacteremia (ICD code A40, A41 or A49).
These diagnoses were choosed because they are the same diagnoses that are used in the national 
pneumonia register. Only adult patients (18 years or older) were included. 
There are four medical clinics in NU-sjukvården: emergency medicine, specialist medicine, neuro-
rehab and cardiology clinic. Only patients from emergency medicine were included in this study. 
There were from the beginning 598 patients, treated in five different wards (three wards in NÄL and 
two wards in Uddevalla hospital).
Patients who were treated in department of infectious diseases directly adjacent to the admission in 
departments of internal medicine were excluded. So were also patients who were treated in any in-
hospital care for the last 30 days and patients who developed the first signs of pneumonia after 48 
hours in hospital, since pneumonia is not considered as community-acquired in these cases. After 
the exclusion, 462 patients remained. 
100 patients were selected with respect to the percentage distribution of main diagnoses among all 
462 patients.
The lists contain patients chronologically arranged by enrollment date. Every fourth patient was 
selected to be included in the study. 
The records were structurally examined and notes were made on a review template determined in 
advance (appendix 1). The information were then compiled in a data file.
Information about 30-days mortality was obtained from population register Västfolket.
 
4. Ethics
Ethical permission was asked for and given by the local ethic comittee (Etikprövningsnämnden). 
The patients were not asked for consent. All information has been treated confidential and personal 
data are not possible to trace. No personal data have been noted on the review template or in the 
data file. Each review template has insted been given a serial number. The study does not cause any 
risk or harm for the patients.
5. Result
5.1 Facts about the sample
54 % of the patients were men and 46 % were women (n=100). Thus, the gender ratio is almost the 
same as in the NQPR, where there were 53.4 % men and 46.6 % women (n=4843). 
The patients were aged 19-97 years and the median age was 80 years (81 years for men and 79 
years for women). The median age is therefore higher than in the NQPR, where median age was 67 
years (67 years for men and 68 years for women).
Table 1. Distribution of main diagnoses according to the ICD-10 system among all patients who 
were treated for community-acquired pneumonia in emergency medicine departments, NU-
sjukvården, during 2012. n=462
ICD code Number of patients Percentage
J18.9 Pneumonia, unspecified 253 54.7 %
J15.9 Bacterial pneumonia, unspecified 168 36.3 %
J13.9 Pneumonia caused by S. pneumoniae 10 2.10 %
J14.9 Pneumonia caused by H. influenzae 3 0.60 %
J15.2 Mycoplasma infection, unspecified site 1 0.20 %
J15.7 Pneumonia caused by M. pneumoniae 8 1.70 %
J15.8 Other specified bacterial pneumonia 3 0.60 %
J16.8 Pneumonia caused by other specified 
infectious organisms
1 0.20 %
J18.0 Bronchopneumonia, unspecified 7 1.67 %
J18.1 Lobar pneumonia, unspecified 4 1.50 %
A41.9 Sepsis, unspecified 3 0.60 %
A41.5 Sepsis caused by other gram-negative 
organisms
1 0.20 %
Table 2. Distribution of main diagnoses according to the ICD-10 system among the patients treated 
in departments of internal medicine who were included in the study. n=100
ICD code Number of patients Percentage
J18.9 Pneumonia, unspecified 55 55.0 %
J15.9 Bacterial pneumonia, unspecified 36 36.0 %
J13.9 Pneumonia caused by S. pneumoniae 2 2.00 %
J15.7 Pneumonia caused by M. pneumoniae 2 2.00 %
J18.0 Bronchopneumonia, unspecified 2 2.00 %
J15.2 Mycoplasma infection, unspecified site 1 1.00 %
J18.1 Lobar pneumonia, unspecified 1 1.00 %
J15.8 Other specified bacterial pneumonia 1 1.00 %
9 % of the patients (11 % of men and 6.5 % of women) died during hospital stay. This is a higher 
mortality than in departments of infectious diseases, where the mortality was 4.0 % (5.1 % among 
men and 2.7 % among women). 4 % more died within 30 days from enrollment day.
The average time of hospital stay was 7.5 days (6.9 days for men and 8.1 days for women) for 
patients who survived (ranging 2-36 days). This is longer than in the NQPR, where the average time 
of hospital stay was 4 days for both men and women. 
Table 3. Co-morbidity among the patients treated in departments of internal medicine. n=100
Co-morbidity Men Women Totally
Chronic heart disease 61.0 % 50.0 % 56.0 %
Chronic lung disease 24.0 % 26.0 % 25.0 %
Neurological disease 31.0 % 22.0 % 27.0 %
Chronic kidney disease 3.70 % 6.50 % 5.00 %
Malignancy 7.40 % 8.70 % 8.00 %
Immunosuppression 2.00 % 0.00 % 1.00 %
Chronic heart disease consisted of cardiac failure, atrial fibrillation, aortic stenosis and coronary 
artery disease.
With chronic lung disease means COPD and asthma.
With neurological disease means MS, Parkinsons disease and cerebrovascular lesions such as 
bleeding or infarction. 
19 % had no co-morbidity.
In the NQPR there were less patients with chronic heart diseases (27.4 %) and neurological diseases 
(16.6 %). There were more patients with immunosuppression (11.3 %). The presence of chronic 
lung disease, chronic kidney disease and malignancy was about the same in both populations.
7 % of the patients were current smokers and 13 % were non-smokers. Information about smoking 
were missing in the enrollment note for 85 % of the patients. Corresponding number in the NQPR 
was 51.9 %. For 5 % there was information about smoking at any other place in the journal, but for 
80 % it remained unclear whether the patient was a smoker or not. 
At time for enrollment, pneumonia was either the most likely diagnosis, one of several diagnoses or 
not mentioned at all. The distribution looked as follows:
Table 4. The assessment at time for enrollment among patients treated in departments of internal 
medicine. n=100
Assessment Men Women Totally
Primarily assessed as pneumonia 61.0 % 41.3 % 52.0 %
One of several possible diagnoses 20.4 % 26.0 % 23.0 %
Not mentioned in the primary assessment 18.5 % 32.6 % 25.0 %
In the NQPR, 66.7 % of the patients were primarily assessed as having pneumonia. In 20.3 % of the 
cases, pneumonia was one of several possible diagnoses and in 10.2 % pneumonia was not 
mentioned in the primary assessment. Information about this was missing in 2.9 % of the patients in 
the NQPR.
There were enough information to calculate the CRB-65-score for 49 % of the patients (52 % of 
men and 46 % of women). The CRB-65-score was however not mentioned in the enrollment note 
for any patient. This compares with the NQPR where there were enough information to calculate 
the CRB-65-score in 84.1 % of the patients and the score was mentioned in 8.5 % of the enrollment 
notes.
41 % had CRB-65-score 0-1, 8 % had CRB-65-score 2-4 and 51 % had an unknown score. In the 
NQPR, 28.2 % of the patients where the score could be calculated, had CRB-65-score 2-4.
Information about confusion was missing for 15 % of the patients (13 % of men and 17 % of 
women). Information about respiratory rate was missing for 47 % (46.3 % of men and 47.8 % of 
women). Information about age and blood pressure were noted for all patients. 
9 % of the patients (11.1 % of men and 6.5 % of women) were treated with CPAP or BiPAP. The 
corresponding number in the NQPR was 4.9 %. Two patients, both women, were treated in ICU. 
One of them was treated in ICU for one day, and one of them was treated in ICU for four days. One 
of them died during hospital stay. In the NQPR, 6.9 % of the patients were treated in ICU. 
Treatment in respirator occured in 1 % of patients from departments of internal medicine and 3 % of 
patients from departments of infectious diseases.
For 13 % of the patients (14.8 of men and 10.9 of women) was a decision about no CPR taken. For 
6 of these patients were also a decision taken to end antibiotic treatment or to refrain from intensive 
care. For one patient it was decided to restrict treatment but descision about no CPR was not taken 
for this patient.
Contact with a specialist in infectious diseases was taken in 13 % of the cases. 9 % were phone 
contact and 4 % were visits. 
5.2 Diagnostics
Radiology was used as diagnostic help in 97 % of the cases. There was a gender difference, with 
more radiological tests for women than for men. When CT was performed, there was usually an 
issue of pulmonary embolism.
Table 5. Radiology as diagnostic help among patients treated in departments of internal medicine. 
n=100
Radiology Men Women Totally
Plain X-ray 92.6 % 80.4 % 87.0 %
CT 1.9 % 10.9 % 6.00 %
Plain X-ray + CT 0.00 % 8.70 % 4.00 %
No radiology 5.50 % 0.00 % 3.00 %
Blood cultures were taken in 83 % of the cases (89 % among men and 76 % among women). The 
corresponding number in the NQPR was 93.1 % (93.7 % among men and 92.4 % among women).
Sputum cultures were taken from 12 % of the patients (16.7 % of men and 6.5 % of women). This 
was more common in the NQPR, where sputum cultures were taken from 26.8 %. 
Nasopharyngeal cultures were taken from 10 % of the patients (5.5 % of men and 15.2 % of 
women). The corresponding number in the NQPR was 66 %. Any airway culture was taken from 21 
% of the patients treated in departments of internal medicine. This is a much lower number than in 
the NQPR, where the corresponding number was 76.3 %.
Mycoplasma serology was taken in 6 % of the cases (7.4 % of men and 4.3 % of women).
PCR for influensa viruses was taken in 3 % of the cases (1.9 % of men and 4.3 % of women). The 
corresponding number in the NQPR was 15.9 %.
Urine sample for pneumococcal antigen detection was taken in 11 % of the patients (11.1 % among 
men and 10.9 % among women). The corresponding number in the NQPR was 32.3 %. Urine 
sample for legionella antigen detection was taken in 9 % of the patients (9.2 % of men and 8.7 % of 
women)
Despite microbiological tests, the etiology remained unclear in 93 % of the cases. The 
corresponding number in the NQPR was 61.6 %. Pneumococci and H. Influenzae was the etiology 
in 2 % each. M. Catharralis was detected in 3 % of the patients. It is noteworthy that the proven 
etiology did not always correspond with the diagnosis that was established. For example, one 
patient got the main diagnosis J15.2 (mycoplasma infection, unspecified site) even though no 
mycoplasma was found in any test, but H. Influenzae was found in a sputum culture from this 
patient. 
5.3 Antibiotics
The initial antibiotic choice was distributed as follows for the entire population from departments of 
internal medicine (n=100):
Figure 1. The initial antibiotic choice among patients treated in departments of internal medicine. 
n=100
58 % received PcV or PcG as initial antibiotic (53.7 % of men and 63 % of women). This is a 
higher number than in the NQPR, where the corresponding numbers were 46.7 %. Additional 16 %  
of the patients (14.8 % of men and 17.4 % of women) treated in departments of internal medicine 
received PcG combined with aminoglycoside (AG).
Cephalosporins were given in 10 % of the cases. 8 % received only cephalosporin and 2 % received 
cephalosporin combined with aminoglycoside. 6.5 % of women received cephalosporins. 
Cephalosporins were given to 9.2 % of men and cephalosporins combined with AG were given to 
3.7 % of the men. Use of cephalosporins was therefore lower than in the NQPR, where 28.6 % 
received cephalosporins. 
The use of PcV or PcG as initial treatment was thus higher for women than for men, and the use of 
cephalosporins was lower among women than among men in the population treated in departments 
of internal medicine. 
The use of piperacillin with tazobactam also differed among the populations. In the NQPR, 8 % 
received this treatment, whereas only 2 % of the patients from departments of internal medicine 
received this kind of antibiotics. 
Quinolones and macrolides were not used at all as initial treatment in departments of internal 
medicine. In the NQPR, 4.7 % got quinolones and 4 % received macrolides.
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The following chart shows the percentage distribution of initial antibiotic choise in departments of 
internal medicine (n=100) and departments of infectious diseases (n=4843):
Figure 2. Percentage distribution of initial antibiotic choise among patients treated in departments 
of internal medicine (n=100) and among patients treated in departments of infectious diseases 
(n=4843)
Use of aminoglycoside is in the NQPR reported as a separate treatment and it is not possible to see 
which kind of antibiotics it was combined with. 
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On the third day in hospital care, it looked like this for the entire population treated in departments 
of internal medicine, that now consisted of 90 patients:
Figure 3. Antibiotic choice on the third treatment day among patients treated in departments of 
internal medicine. n=90
67 % (62 % of men and 72.5 % of women) received PcV or PcG. The corresponding number in the 
NQPR was 37.3 %. Patients who got PcG combined with aminoglycoside had decreased to ony one 
patient (1.1 %). 8.9 % (10 % of men and 7.5 % of women) still received cephalosporins. This is 
however a lower number than in the NQPR, where 14.6 % of the patients received cephalosporins 
on the third day. 
4.4 % of patients from departments of internal medicine received amoxicillin on the third day. The 
corresponding number in the NQPR was 12 %.
3.3 % (three patients) did not get any antibiotics on the third day. In two of these cases there was a 
palliative desicion taken to end treatment because the patients were too ill, and these patients died 
later. In the third case, the patient received antibiotics again a few days later and the reason for the 
break in the tretment was not clear. 
Like on the first day, there were a greater proportion of women than men who received PcV or PcG. 
Amoxicillin was also more common among women than among men (7.5 % compared with 2 %).
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The following table shows the percentage distribution of antibiotic choise on the third day:
Departments of internal medicine: (n=90)
Departments of infectious diseases: (n=4843)
Figure 4. Percentage distribution of antibiotic choise on the third treatment day among patients 
treated in departments of internal medicine (n=90) and among patients treated in departments of 
infectious diseases (n=4843)
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The final treatment in hospital or at home for the patients who survived (n=91) was distributed as 
follows for the entire population:
Figure 5. Final antibiotic treatment among surviving patients treated in departments of internal 
medicine. n=91
51.6 % (45.8 % of men and 58.1 % of women) received PcV, which is a higher number than in the 
NQPR, where 27.9 % got this final treatment. 2 % were still given cephalosporins, and the 
corresponding number in the NQPR was 1.3 %. 
Use of doxycyklin increased from 6.6 % on the third day to 17.6 % as final treatment (20.8 % of 
men and 14 % of women). 13 % of the patients from the NQPR got doxycyklin as final treatment. 
Use of amoxicillin increased from 4.4 % on the third day to 15.4 % (12.5 % of men and 18.6 % of 
women) as final treatment. 21.9 % in the NQPR received amoxicillin as final treatment. Quinolones 
were more common as final treatment in the NQPR, where 9.1 % got this, compared with only 1 % 
of the patients treated in departments of internal medicine.
Thus, there was a gender difference as women received more PcV and amoxicillin, and less 
doxycyklin than men received as final treatment. 
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The following table shows the percentage distribution of final antibiotic choise in departments of 
internal medicine and departments of infectious diseases:
Departments of internal medicine: (n=91)
Departments of infectious diseases: (n=4843)
Figure 6. Percentage distribution of final antibiotic treatment among surviving patients treated in 
departments of internal medicine (n=91) and among patients treated in departments of infectious 
diseases (n=4843)
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The average time for intravenous antibiotic therapy was 3.6 days (4 days for men and 3 days for 
women) for surviving patients treated in departments of internal medicine.
The total treatment time, including policlinic treatment, exceeded in most cases the recommended 
seven days. 82.4 % of the patients who survived got antibiotics 8 days or longer (85.4 % of men and 
79.1 % of women). 
Figure 7. Total treatment time with antibiotics among surviving patients treated in departments of 
internal medicine. n=91
In the NQPR, 68.4 % got antibiotic treatment 8 days or longer.
Figure 8. Total treatment time with antibiotics among surviving patients in departments of internal 
medicine (n=91) and departments of infectious diseases (n=4843)
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Other factors that had an impact on the choise of initial antibiotic treatment was oxygen saturation, 
body temperature, CRP (C-reactive protein detected in blood sample) and co-morbidity.
Table 6. Selection of cephalosporins and PcG/PcV as initial treatment at various levels of oxygen 
saturation among patients treated in departments of internal medicine with a known oxygen 
saturation. n=99
Oxygen saturation, % Cephalosporins PcG/PcV Other antibiotics
< 89                    n=20 15.0 % 70.0 % 15.0 %
90-95                  n=49 10.2 % 51.0 % 38.8 %
96-100                n=30 3.30 % 63.3 % 33.4 %
Table 7. The selection of cephalosporins and PcG/PcV as initial treatment at various levels of body 
temperature among patients treated in departments of internal medicine with a known body 
temperature. n=95
Body temperature Cephalosporins PcG/PcV Other antibiotics
< 38.4              n=73 6.85 % 60.3 % 32.9 %
>38.5               n=22 13.6 % 45.5 % 40.9 %
Table 8. The selection of cephalosporins and PcG/PcV as initial treatment at various CRP levels 
among patients treated in departments of internal medicine. n=100
CRP Cephalosporins PcG/PcV Other antibiotics
< 100                  n=51 5.90 % 56.9 % 37.2 %
>101                   n=49 10.2 % 59.2  % 30.6 %
The co-morbidity also had an impact on the choice of initial antibiotic treatment. 
Table 9.  The selection of cephalosporins and PcG/PcV as initial treatment among patients with 
various types of co-morbidity treated in departments of internal medicine. n=100
Co-morbidity PcG/PcV PcG+AG Cephalosporins Cephalosporins+AG
Chronic heart disease    n=56 55.3 % 16.0 % 7.10 % 3.60 %
Chronic lung disease     n=25 50.0 % 23.0 % 7.70 % 7.70 %
Neurological disease    n=27 59.3 % 14.8 % 14.8 % 3.70 %
Entire population         n=100 58.0 % 16.0 % 8.00 % 2.00 %
6. Discussion and conclusion
6.1 Discussion
There were less patients with severe pneumonia among patients treated in departments of internal 
medicine than in the NQPR, but it is important to take into account the large number of patients 
where CRB-65-score could not be calculated. Where the CRB-65-score could not be calculated, no 
one can know how severely ill the patients actually were. 
CRB-65-score were not used at all in the management of patients with suspected pneumonia. This 
might be because of the informal local procedures, or simply by lack of time. Another explanation 
could be that the doctors do not consider CRB-65-score as a good enogh predictive tool. The CRB-
65-score has nevertheless been criticized in some studies. 
For example, a spanish study criticizes the method for not taking into account the patients oxygen 
saturation. The same study also indicates that an age limit of 65 years is not so good, especially 
among elderly patients, as it means that all elderly patients automatically gets one point for age in 
the score, regardless how ill they are. The authors conclude that, besides confusion, high respiratory 
rate and a low blood pressure, oxygen saturation < 90 % and age > 75 years are the best factors for 
predicting 30-day mortality [4]. Another spanish study concludes that changing the age criteria from 
65 years to 75 years is better for predicting 30-day mortality, especially among elderly patients over 
65 years. [22]
CRB-65 is however not the only tool that can be used for assessing the severity of pneumonia. Two 
other methods that are widely used abroad are PSI (Pneumonia Severity Index) and CURB-65. The 
PSI is primarily used in the US, and was originally developed to identify patients with mild 
pneumonia taht could be treated in primary care. It takes into account both clinical findings, 
demographic factors such as age and sex, and laboratory findings [23]. It has been criticized fo 
being too complex. CURB-65 is a easier method, that takes into account confusion, urea levels in 
blood, respiratory rate, blood pressure and age [24]. A chinese study containing 1016 pneumonia 
patients concludes that all three methods are equally good for assessing the severity of the disease. 
[25]
None of the methods mentioned above were used, however. When taking into account that CRB-65 
is an even easier method, which is based only on clinical findings and do not require any laboratory 
tests, it is a little remarkable that it is not used more often. 
Instead of CRB-65; temperature, oxygen saturation and CRP seemed to be the most important 
parameters when assessing illness severity and by that choose treatment. This was most evident 
regarding how many patients who received cephalosporins as initial treatment. 
Several research studies has investigated the role of oxygen saturation in the management of 
patients with community-acquired pneumonia. A british study containing 467 patients examined the  
importance of oxygen saturation in predicting 30-day mortality and need of intensive care. The 
conclusion was that a saturation limit of 90 % was best for predicting these serious consequences. 
[26]
A canadian study containing 2923 patients also concluded that oxygen saturation <90 % was 
associated with more severe illness and increased 30-day mortality, and suggests 92 % as the best 
threshold value when assessing pneumonia severity. [27]
Chalmers et al studied the effects of CRP on the assessment of illness severity. The study contained 
570 patients with community-acquired pneumonia and they concluded that a low CRP (<100) at 
time for admission was the most important factor for predicting 30-day mortality, need for 
ventilation support and/or complications such as abscesses and empyema. They also found that if 
the CRP had not decreased with 50 % on the fourth day of illness, there was an increased risk for 
30-day mortality, need for ventilation support and complications. The study concluded that a high 
CRP (>100) was correletad with severe disease, while a low CRP (<100) was not as strongly 
correlated with mild disease. [28]
Regarding CRP, it is however important to think about when the patient seeks medical care. CRP 
does not rise immediately when the illness starts. If the patient seeks medical care early, the CRP 
might not have started to rise yet, while other signs of severe illness, such as high body temperature, 
low oxygen saturation or high respiratory rate, can be present. That means, the physician can assess 
the illness as severe even though the patient has a low CRP.
If assuming the use of cephalosporins means that the disease was assessed as more severe, a similar 
result was found in the study in NU-sjukvården. A high CRP (>101) was in fact correlated with a 
higher incidence of cephalosporin use (see table 8), and the disease was thus more often considered 
to be severe. A low CRP (<100), however, was not as strongly correlated with the assessment of 
illness severity. If assuming that use of PcG or PcV means that the disease was assessed as less 
severe, one could see that the CRP did not have as much impact on the antibiotic choise. PcG and 
PcV were in fact choosed approximately equally regardless of wheter the CRP was high or low.
The choice of only PcV or PcG as initial treatment is not so much influenced by the co-morbidity, 
but one can see that it was more likely to choose cephalosporins when the patient had an underlying  
neurological disease (see table 9). When taking into account both cephalosporins and 
cephalosporins combined with aminoglycoside, it is clear that both neurological disease and chronic 
lung disease increases the probability of choosing this treatment. When the patient has an 
underlying chronic lung disease, it is more likely to use aminoglycoside as a supplement to the 
initial penicillin or cephalosporin treatment. 
Mortenson et al studied the causes of death among patients with community-acquired pneumonia, 
and they concluded that the three most important underlying factors for increased risk of death 
among these patients was lung cancer, ischemic heart disease and neurological conditions such as 
cerebro-vascular lesions, amyotrophic lateral sclerosis, Parkinsons disease, myastenia gravis and 
multiple sclerosis. [29]
In the study in NU-sjukvården one could see a similar result regarding the underlying neurological 
diseases. They were more often were treated with cephalosporins, assuming this means that the 
physician assessed the patients as more severe ill and ran a higher risk of dying from their disease. 
However, one could not see the same result regarding the underlying ischemic heart diseases (in 
table 9 reported under ”chronic heart disease”). These patients did not get cephalosporins more 
often than the population as a whole. Regarding patients with chronic lung diseases, they received 
both cephalosporins and PcG/PcV in approximately the same extent as the population as a whole, 
but the difference was that these patients got added aminoglycoside more often. This can also be a 
sign that the physician assessed the disease as more severe.
Total antibiotic treatment time is recommended to be 7 days for patients with pneumonia. This was 
in most cases exceeded. Treatment time were longer in departments of internal medicine than in 
departments of infectious diseases (see figure 8). It seems like it is common to prescribe a seven day 
course of peroral antibiotics when the patient is discharged no matter how long the intravenous 
treatment had lasted. This may be because the number of tablets in the package often are adapted to 
seven days treatment. Another explanation may be that the physician considers a shorter course of 
treatment as less effective. 
There has, however, been several studies showing that a treatment time of seven day or shorter is 
not worse for the patient than a longer treatment time. An american meta-analysis contained in total 
2796 patients with community-acquired pneumonia. The patients had received antibiotics for either 
less than seven days or more than seven days. The researchers concluded there were no difference 
between the two groups regarding mortality, eradication of bacterias or failure to achieve clinical 
improvement. [30] A greek meta-analysis drawed the same conclusion; there were no differences in 
mortality, clinical improvement, adverse events or relapses among the pneumonia patients who got 
a short antibiotic course compared with the patients who got a longer course. [31]
In the study in NU-sjukvården, one could see that among the patients who received antibiotics for 
seven days or less, the mortality was lower than among the patients who got antibiotics eight days 
or more. This applies both to in-hospital mortality and 30-day mortality, as all patients who got the 
shorter treatment time were alive after 30 days. It is however important to keep in mind that there 
were only 16 patients in this group, meaning one should be cautious in drawing firm conclusions 
from this.  
Airway cultures were taken far too infrequently in relation to the set target. This might be because it 
is regarded as difficult to get a good airway sample that is not contaminated with mouth- and 
pharynx flora. Lack of time can be another explanation. Since it is difficult for the patient to 
produce a sputum sample, it is sometimes necessary to get help from a physiotherapist who can 
instruct the patient how he or she should do to produce a good sample. In practice this is often not 
possible, since patients generally seeks medical care at the emergency department where 
physiotherapists are rarely available. 
Another explanation may be that physicians consider the sputum culture has insufficient specificity 
and sensitivity to influence the treatment. A german study with 116 patients with community-
acquired pneumonia concluded that it was difficult to get the sputum culture fast enough before 
antibiotic treatment was started. Further, only 36 % of the patients were able to produce any sputum 
at all, and only 9 % of the samples were representative for the lower airways.[32] There were much 
more airway cultures taken in infection clinics, and this may be because infection staff have a 
greater habit of taking cultures generally.  
In the population treated in departments of internal medicine one could see some gender differences 
in both investigation and treatment of pneumonia. For example, both blood cultures and airway 
cultures were taken more frequently among men. Radiology was used more frequently as a 
diagnostic help among the female patients. It could be interesting to study this more and try to find 
an explanation to the differences.
6.2 Strenghts and weaknesses
The medical records were selected systematic from a list of all patiens arranged in chronological 
order by enrollment date. In this way, the sample reflected the distribution of patiens during the 
year.
All patients, regardless sex, age or co-morbidity, had the same chance to be selected for the study. 
Thus, the sample reflects the whole population. 
Since there were only 100 records in the study, it is important to be cautious in making conclusions 
about percentage differences in treatment. Especially when a kind of antibiotics is given to only a 
couple of patients, there will be big percentage differences if treatment is changed for one patient.
Information to count the CRB-65-score were often missing, and therefore it was not possible to 
divide the material into two groups and present patients with mild and severe pneumonia separately.
6.3 Conclusions
The target to count and note CRB-65-score for at least 50 % of the patients at time for enrollment 
was not achieved neither in departments of internal medicine nor in  departments of infectious 
diseases, but there was a higher rate among the latter.
The target to take airway cultures from all partients with suspected pneumonia was not achieved in 
departments of internal medicine, and there were fewer airway cultures taken in these departments 
compared with departments of infectious diseases.
Blood cultures were also less in departments of internal medicine than in departments of infectious 
diseases, and the target to take blood cultures from all patients was not really achieved.
PcV or PcG was given alone or combined with aminoglycoside as initial treatment for 74 % of the 
patients in departments of internal medicine, regardless the CRB65-score. Thus, the target to treat at 
least 75 % with these antibiotics was almost achieved. The departments of internal medicine used 
more PcV/PcG than departments of infectious diseases.
7. Populärvetenskaplig sammanfattning
Lunginflammation är en vanlig sjukdom som förr i tiden ofta kunde leda till döden, men som nu för 
tiden ofta kan behandlas framgångsrikt med antibiotika. I takt med att användningen av antibiotika 
har ökat har vissa typer av bakterier utvecklat motståndskraft, så kallad resistens, mot en del typer 
av antibiotika. För att motverka resistensutvecklingen är det viktigt att använda rätt sorts 
antibiotika. Ett bra sätt att välja rätt antibiotika är att fastställa vilken typ av bakterie som orsakat 
sjukdomen. Detta kan göras genom att ta odlingar från exempelvis blod och luftvägar. 
Svenska infektionsläkarföreningen har satt upp ett antal mål gällande vården av de patienter som 
vårdas inneliggande för lunginflammation på sjukhusens infektionskliniker. Målen innebär att alla 
patienter ska blododlas och minst 75 % ska luftvägsodlas. Vidare ska man använda hjälpmedlet 
CRB-65 när man väljer antibiotika. CRB-65 är ett snabbt sätt att bedöma hur allvarligt sjuk 
patienten är, och därmed vilken antibiotika som bör väljas i första hand. CRB-65 tar hänsyn till 
patientens ålder, blodtryck, andningsfrekvens och ifall akut förvirring föreligger. Patienter som har 
låga poäng på CRB-65 anses inte vara allvarligt sjuka och skall behandlas med vanligt penicillin i 
första hand. Vanligt penicillin innebär endast en liten risk för resistensutveckling.
De flesta patienter som vårdas på sjukhus för lunginflammation vårdas dock inte på 
infektionskliniker utan på medicinkliniker. Det är därför intressant att undersöka i vilken 
utsträckning Infektionsläkarföreningens mål nås på medicinkliniker.
I den här studien har vi granskat 100 journaler från patienter som vårdades för lunginflammation på 
medicinklinik i NU-sjukvården (NÄL och Uddevalla sjukhus) 2012 och jämfört med data ur 
Infektionsläkarföreningens nationella register över patienter som vårdats för lunginflammation på 
infektionskliniker. 
Studien visar att CRB-65 inte användes alls på medicinklinik. Det togs lite mindre blododlingar och 
mycket mindre luftvägsodlingar på medicinklinik än på infektionsklinik. Däremot var det en större 
andel av patienterna på medicinklinik som behandlades med vanligt penicillin.
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Appendix
Journalgranskningsmall
Mall för journalgranskning av utskrivna patienter med samhällsförvärvad pneumoni enligt ICD10- 
diagnoserna J13-J18 (oavsett fjärde position). Pneumoni ska vara antingen huvuddiagnos, eller 
bidiagnos till bakteriemi (A40,A41 eller A49)
Löpnummer_______________________________________
Födelseår__________________________________________
Kön_______________________________________________
ICD-10 diagnos_____________________________________
Antal vårddagar (Påbörjad dag=1dag,inskrivningsdag=1dag, utskrivningsdag=1dag, minus 
permission)_________________________________________
Avliden under vårdtiden JA       NEJ
Avliden inom 30 dagar från och med inläggningsdag JA       NEJ
Bakomliggande sjukdomar, enligt journal från vårdtillfället
Kronisk hjärtsjukdom ( Hjärtsvikt, ischemisk hjärtsjukdom) JA        NEJ    
Kronisk lungsjukdom (måttlig-svår KOL/Astma eller dylikt) JA        NEJ        
Neurologisk sjukdom JA        NEJ        
Kronisk njursvikt JA        NEJ        
Aktiv tumörsjukdom JA        NEJ        
Immunkomprometterande sjukdom JA        NEJ        
(aktiv tumörsjukdom, HIV, Immunosuppressiv behandling)
Rökare JA        NEJ   OKÄNT      
Finns uppgift om rökning i inskrivningsjournalen JA        NEJ
Misstanke om pneumoni vid inläggningen, enligt inskrivningsjournalen 
Primär inläggningsdiagnos En av flera differentialdiagnoser      Pneumoni omnämns ej
 
CRB-65 vid ankomst till sjukhus (första värdet inom 24 h)
C: nytillkommen konfusion eller sänkt medvetandegrad     JA      NEJ       EJ REGISTRERAD
R: respiration ≥ 30/min        JA      NEJ       EJ REGISTRERAD
B: blodtryck, systoliskt <90 mmHg eller    JA       NEJ       EJ REGISTRERAD
diastoliskt ≤60 mmHg 
Summa CRB-65 vid ankomst (0-4)          0      1      2      3      4     KAN EJ BERÄKNAS
Nämns CRB-65 poäng i inskrivningsjournalen? JA       NEJ 
Syrgasmättnad tagen vid ankomst? (ingår ej i CRB-65) JA NEJ 
Syrgasmättnad mätvärde ( första tagna värdet) _______________________
Infektionsparametrar
Kroppstemperatur tagen  JA NEJ
Om ja, temperatur mätvärde ( första tagna värdet)____________
CRP tagen JA NEJ
Om ja, CRP mätvärde ( första tagna värdet)__________________
LPK tagen JA NEJ
Om ja, LPK mätvärde ( första taget värdet)___________________
Infektionskonsult
Kontakt med infektionskonsult JA NEJ
Om ja, ange typ av konsultation TELEFON    BESÖK
Lungröntgen
Är lungröntgen utförd? JA NEJ
Vilken typ av lungröntgen är utförd ?________________________
Tolkar radiologen bilden som en pneumoni? JA NEJ
Tolkar klinikern bilden som en pneumoni? JA    NEJ    GÅR EJ ATT BEDÖMA
Diagnostik och Etiologi
Blododling tagen JA NEJ 
Luftvägsodling på sputum tagen JA NEJ 
Luftvägsodling på nasofarynxsekret tagen JA NEJ 
Luftvägsodling BAL/skyddad borste tagen JA NEJ
PCR för luftvägsagens JA NEJ 
PCR för Mycoplasma JA NEJ 
PCR för Legionella JA NEJ 
PCR för Virus JA NEJ 
Pneumokockantigen i urin JA NEJ 
Legionellaantigen i urin JA NEJ 
Mikrobiologiskt agens påvisat? JA NEJ
Om ja, ange : 
Pneumokocker      H. influenzae      Mykoplasma      C. pneumoniae      Legionella 
S. aureus      Annan bakterie      Influensavirus      Annat virus 
Hur ställdes den etiologiska diagnosen (ett eller flera val)?
Blododling      Luftvägsodling (sputum)      Luftvägsodling (nasopharynx)      
Luftvägsodling  (BAL/borste)      PCR      Urinantigen      Serologi      Annat
Pågående antibiotikabehandling vid ankomst till sjukhus JA NEJ
Initialt antibiotikaval på sjukhuset (ett eller flera val)
Penicillin V eller G Amoxicillin   Amoxi/Clav 
Cefalosporin Kinolon   Makrolid 
Doxycyklin Klindamycin   Aminoglykosid 
Pip/tazo Karbapenem   Övrig antibiotika
Antiviral beh. mot influensa   Ingen antibiotika
Antibiotikaval dag 3 på sjukhuset (ett eller flera val)
Penicillin V eller G Amoxicillin   Amoxi/Clav 
Cefalosporin Kinolon   Makrolid 
Doxycyklin Klindamycin   Aminoglykosid 
Pip/tazo Karbapenem   Övrig antibiotika
Antiviral beh. mot influensa   Ingen antibiotika
Utskriven med/avslutande antibiotikabehandling:
Penicillin V eller G Amoxicillin     Amoxi/Clav  
Cefalosporin Kinolon     Makrolid
Doxycyklin Klindamycin     Aminoglykosid 
Pip/tazo Antiviral beh. mot influensa      Övrig antibiotika
Ingen antibiotika
Antalet dygn med intravenös antibiotikabehandling?__________________ 
Antalet behandlingsdygn med antibiotika inkl poliklinisk behandling
<=7 dagar 8-10 dagar 11-14 dagar  >14 dagar
Intensivvård
IVA-vård JA NEJ
CPAP/BiPAP JA NEJ
Respiratorvård JA NEJ
Om intensivvård, ange antalet dagar ?(Påbörjad dag=1dag) _______________________
Togs någon typ av palliativt beslut, såsom att inskränka eller avbryta behandlingen ?   
JA NEJ
Beslutades det om 0-HLR ? JA NEJ 
